Cargando…
Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
Objective. To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) patients with the therapy of subcutaneous (subQ) administration of bortezomib and dexamethasone plus thalidomide (VTD) regimen. Methods. A total of 60 newly diagnosed MM patients were anal...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575715/ https://www.ncbi.nlm.nih.gov/pubmed/26425561 http://dx.doi.org/10.1155/2015/927105 |
_version_ | 1782390803884146688 |
---|---|
author | Wu, Shenghao Zheng, Cuiping Chen, Songyan Cai, Xiaoping Shi, Yuejian Lin, Bijing Chen, Yuemiao |
author_facet | Wu, Shenghao Zheng, Cuiping Chen, Songyan Cai, Xiaoping Shi, Yuejian Lin, Bijing Chen, Yuemiao |
author_sort | Wu, Shenghao |
collection | PubMed |
description | Objective. To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) patients with the therapy of subcutaneous (subQ) administration of bortezomib and dexamethasone plus thalidomide (VTD) regimen. Methods. A total of 60 newly diagnosed MM patients were analyzed. 30 patients received improved VTD regimen (improved VTD group) with the subQ injection of bortezomib and the other 30 patients received conventional VTD regimen (VTD group).The efficacy and safety of two groups were analyzed retrospectively. Results. The overall remission (OR) after eight cycles of treatment was 73.3% in the VTD group and 76.7% in the improved VTD group (P > 0.05). No significant differences in time to 1-year estimate of overall survival (72% versus 75%, P = 0.848) and progression-free survival (median 22 months versus 25 months; P = 0.725) between two groups. The main toxicities related to therapy were leukopenia, neutropenia, thrombocytopenia, asthenia, fatigue, and renal and urinary disorders. Grade 3 and higher adverse events were significantly less common in the improved VTD group (50%) than VTD group (80%, P = 0.015). Conclusions. The improved VTD regimen by changing bortezomib from intravenous administration to subcutaneous injection has noninferior efficacy to standard VTD regimen, with an improved safety profile and reduced adverse events. |
format | Online Article Text |
id | pubmed-4575715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-45757152015-09-30 Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients Wu, Shenghao Zheng, Cuiping Chen, Songyan Cai, Xiaoping Shi, Yuejian Lin, Bijing Chen, Yuemiao Biomed Res Int Research Article Objective. To investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (MM) patients with the therapy of subcutaneous (subQ) administration of bortezomib and dexamethasone plus thalidomide (VTD) regimen. Methods. A total of 60 newly diagnosed MM patients were analyzed. 30 patients received improved VTD regimen (improved VTD group) with the subQ injection of bortezomib and the other 30 patients received conventional VTD regimen (VTD group).The efficacy and safety of two groups were analyzed retrospectively. Results. The overall remission (OR) after eight cycles of treatment was 73.3% in the VTD group and 76.7% in the improved VTD group (P > 0.05). No significant differences in time to 1-year estimate of overall survival (72% versus 75%, P = 0.848) and progression-free survival (median 22 months versus 25 months; P = 0.725) between two groups. The main toxicities related to therapy were leukopenia, neutropenia, thrombocytopenia, asthenia, fatigue, and renal and urinary disorders. Grade 3 and higher adverse events were significantly less common in the improved VTD group (50%) than VTD group (80%, P = 0.015). Conclusions. The improved VTD regimen by changing bortezomib from intravenous administration to subcutaneous injection has noninferior efficacy to standard VTD regimen, with an improved safety profile and reduced adverse events. Hindawi Publishing Corporation 2015 2015-09-06 /pmc/articles/PMC4575715/ /pubmed/26425561 http://dx.doi.org/10.1155/2015/927105 Text en Copyright © 2015 Shenghao Wu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wu, Shenghao Zheng, Cuiping Chen, Songyan Cai, Xiaoping Shi, Yuejian Lin, Bijing Chen, Yuemiao Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients |
title | Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients |
title_full | Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients |
title_fullStr | Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients |
title_full_unstemmed | Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients |
title_short | Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients |
title_sort | subcutaneous administration of bortezomib in combination with thalidomide and dexamethasone for treatment of newly diagnosed multiple myeloma patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575715/ https://www.ncbi.nlm.nih.gov/pubmed/26425561 http://dx.doi.org/10.1155/2015/927105 |
work_keys_str_mv | AT wushenghao subcutaneousadministrationofbortezomibincombinationwiththalidomideanddexamethasonefortreatmentofnewlydiagnosedmultiplemyelomapatients AT zhengcuiping subcutaneousadministrationofbortezomibincombinationwiththalidomideanddexamethasonefortreatmentofnewlydiagnosedmultiplemyelomapatients AT chensongyan subcutaneousadministrationofbortezomibincombinationwiththalidomideanddexamethasonefortreatmentofnewlydiagnosedmultiplemyelomapatients AT caixiaoping subcutaneousadministrationofbortezomibincombinationwiththalidomideanddexamethasonefortreatmentofnewlydiagnosedmultiplemyelomapatients AT shiyuejian subcutaneousadministrationofbortezomibincombinationwiththalidomideanddexamethasonefortreatmentofnewlydiagnosedmultiplemyelomapatients AT linbijing subcutaneousadministrationofbortezomibincombinationwiththalidomideanddexamethasonefortreatmentofnewlydiagnosedmultiplemyelomapatients AT chenyuemiao subcutaneousadministrationofbortezomibincombinationwiththalidomideanddexamethasonefortreatmentofnewlydiagnosedmultiplemyelomapatients |